EMA backs Novo’s Wegovy pill as a new chapter for obesity treatment in Europe

The European Medicines Agency has recommended approval for Novo Nordisk’s oral version of Wegovy, potentially making it the first oral GLP-1 treatment for weight management in Europe. If formally approved by the European Commission, the once-daily tablet would offer patients a new alternative to injectable obesity therapies and mark another major step in the fast-growing weight management market.

Wegovy is already known as a weekly injectable treatment based on semaglutide, the same active ingredient used in Ozempic. The oral formulation uses the same therapeutic pathway, helping regulate appetite, increase feelings of fullness, and reduce hunger and cravings. According to Reuters, clinical trial data showed average weight loss of 16.6% among patients taking the pill, compared with far lower results in the placebo group.

For patients, the biggest change may be convenience. Injectable GLP-1 therapies have reshaped obesity care, but injections can still be a barrier for some people. A daily pill could make treatment feel more accessible, less intimidating, and easier to integrate into routine care. At the same time, oral Wegovy is not necessarily simpler in every respect. It must be taken while fasting and without other medications, which may affect adherence for some patients.

The decision also comes at a time when competition in obesity treatment is intensifying. Novo Nordisk has dominated much of the GLP-1 conversation through Ozempic and Wegovy, while Eli Lilly has been rapidly expanding its own obesity portfolio. Oral treatments are now becoming a major focus, not only because of patient preference, but also because they could reshape prescribing patterns, access discussions, and long-term treatment expectations.

Still, regulatory support is only one part of the story. Access across Europe will likely vary by country, depending on pricing, reimbursement, healthcare system priorities, and whether obesity medicines are managed through specialist care or broader primary care pathways. Even with approval, the real-world impact of oral Wegovy will depend on how quickly patients can actually receive it.

For physicians, this development raises practical questions. Which patients may benefit most from an oral formulation? How will adherence compare with weekly injections? Will oral GLP-1 therapy expand access, or mainly offer another option to patients already eligible for treatment? And how should clinicians discuss expectations around long-term use, lifestyle support, tolerability, and discontinuation?

The EMA’s recommendation does not yet mean final approval, but it is a significant milestone. Obesity care is moving quickly from a limited set of interventions toward a more diverse treatment landscape, with different formats, mechanisms, and patient preferences shaping clinical decisions. If approved, oral Wegovy could become more than just a new version of an existing drug. It may signal the next stage in how obesity treatment is delivered, discussed, and normalized across Europe.

G-Med excels in HCP marketing by blending digital innovation with data-driven insights, creating an effective platform for reaching healthcare professionals, offering various advertising solutions. By using G-Med to engage HCPs, share data reports, and explore innovative channels, marketers can deliver targeted, impactful messages that foster strong connections. G-Med’s approach ensures that each campaign is tailored, scientifically rigorous, and effective, aligning perfectly with the best practices for successful HCP marketing.   

Contact us today to learn more: Contact@g-med.com